Osteogenic Growth Peptide (10-14) (OGP(10-14)), the C-terminal truncated pentapeptide of osteogenic growth peptide (OGP), retains the full OGP-like activity. Osteogenic Growth Peptide (10-14) is responsible for the binding to the OGP receptor and activates an intracellular Gi-protein-MAP kinase signaling pathway. Osteogenic Growth Peptide (10-14) is a potent mitogen and stimulator of osteogenesis and hematopoiesis. Osteogenic Growth Peptide (10-14) acts as a Src inhibitor. In Vitro Osteogenic Growth Peptide (10-14) (OGP(10-14)) induces proliferation and differentiation in fibroblast and osteoblast cell lines. Osteogenic Growth Peptide (10-14) induces TPO-primed M07-e cells differentiation through RhoA/TGFβ1/SFKs signalling pathway. In particular Historphin acts as a Src inhibitor, showing the same effects of PP2 . MCE has not independently confirmed the accuracy of these methods. They are for reference only. In Vivo Osteogenic Growth Peptide (10-14) (OGP(10-14)) increases bone formation and trabecular bone density and stimulates fracture healing when administered to mice and rats . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Form:Solid